Showing results (1-10 of 11) with videos related to
Sort By:
Pageof 2
Journal of Clinical Epidemiology|May 12, 2007
A method is presented to plan the required sample size when estimating regression-based reference limitsCarine A Bellera, James A HanleyAnnals of Epidemiology|April 1, 2008
Hierarchical changepoint models for biochemical markers illustrated by tracking postradiotherapy prostate-specific antigen series in men with prostate cancerCarine A Bellera, James A Hanley, Lawrence Joseph, et al.International Journal of Radiation Oncology, Biology, Physics|April 28, 2009
A statistical evaluation of rules for biochemical failure after radiotherapy in men treated for prostate cancerCarine A Bellera, James A Hanley, Lawrence Joseph, et al.American Journal of Epidemiology|February 28, 2008
Detecting trends in noisy data series: application to biomarker seriesCarine A Bellera, James A Hanley, Lawrence Joseph, et al.Journal of Geriatric Oncology|February 13, 2016
Detection of frailty in elderly cancer patients: Improvement of the G8 screening testAurélie Petit-Monéger, Muriel Rainfray, Pierre Soubeyran, et al.BMC Medical Research Methodology|March 18, 2010
Variables with time-varying effects and the Cox model: some statistical concepts illustrated with a prognostic factor study in breast cancerCarine A Bellera, Gaëtan MacGrogan, Marc Debled, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 14, 2019
Activity and Safety of Palbociclib in Patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Biomarker-driven Phase II StudyMaud Toulmonde, Jean-Yves Blay, Olivier Bouche, et al.European Journal of Cancer (Oxford, England : 1990)|November 6, 2012
Protocol of the Definition for the Assessment of Time-to-event Endpoints in CANcer trials (DATECAN) project: formal consensus method for the development of guidelines for standardised time-to-event endpoints' definitions in cancer clinical trialsCarine A Bellera, Marina Pulido, Sophie Gourgou, et al.Nature Cancer|April 9, 2025
Regorafenib plus avelumab in advanced gastroenteropancreatic neuroendocrine neoplasms: a phase 2 trial and correlative analysisSophie Cousin, Jean-Philippe Guégan, Lola Jade Palmieri, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 25, 2013
Functional decline in older patients with cancer receiving first-line chemotherapyStéphanie Hoppe, Muriel Rainfray, Marianne Fonck, et al.Pageof 2